In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries. This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA.
In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries.
This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA. Purvis is the director of health services research at the AARP Public Policy Institute, where she leads a team of policy analysts and researchers who work on health care issues that are relevant to the population of Americans aged 50 or older.
We discussed the drug pricing report, the burden that older Americans face from high out-of-pocket costs, and possible policy solutions.
Read more about the AARP report, the White House Council of Economic Advisors report, and AARP’s Stop Rx Greed campaign.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.